Stocks Health care TNGX
NASDAQ · Health careTango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $208M. In fiscal 2025 capital spending exceeded operating cash flow by $139.9M. At September 30, 2026 it held $86.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Tango Therapeutics, Inc.
- Net worth
- Tango Therapeutics, Inc. has a market value (market cap) of $3.6B at the latest share price, and shareholders' equity of $980.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $62.4M (+48.3% year on year), with a net loss of $101.6M. Over the 12 months to September 30, 2026: revenue $0, net loss $208M.
- Cash flow
- In fiscal 2025 operations used $138.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tango Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Tango Therapeutics, Inc. does
Tango Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TNGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $62.4M | -$101.6M | -$0.87 | -$139.9M |
| 2024 | $42.1M | -$130.3M | -$1.19 | -$132.3M |
| 2023 | $36.5M | -$101.7M | -$1.08 | -$119.5M |
| 2022 | $24.9M | -$108.2M | -$1.23 | -$116.8M |
| 2021 | $37M | -$58.2M | -$0.94 | -$61.4M |
| 2020 | $7.7M | -$52M | -$1.63 | $69M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TNGX ranks in Health care
Latest SEC filings
What Tango Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- October 23, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Tango Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.7M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Newcomb JessicaPrincipal Accounting Officer | Soldpre-planned (10b5-1) | 5,571 | $124.1K |
| November 2, 2026 | Newcomb JessicaPrincipal Accounting Officer | Soldpre-planned (10b5-1) | 1,460 | $33.6K |
| November 2, 2026 | Crystal AdamPresident, R&D | Exercised options | 5,000 | $14.6K |
| November 2, 2026 | Crystal AdamPresident, R&D | Soldpre-planned (10b5-1) | 3,900 | $86.8K |
| November 2, 2026 | Crystal AdamPresident, R&D | Soldpre-planned (10b5-1) | 1,100 | $25.3K |
| October 1, 2026 | Crystal AdamPresident, R&D | Exercised options | 27,000 | $140.4K |
| October 1, 2026 | Crystal AdamPresident, R&D | Soldpre-planned (10b5-1) | 26,400 | $645.6K |
| October 1, 2026 | Crystal AdamPresident, R&D | Soldpre-planned (10b5-1) | 600 | $15.2K |
Who owns TNGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Davis Aaron I.13D, may seek influence with 3 related filers | 10% | January 2, 2025 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 9.8% | August 14, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 9.3% | May 15, 2026 |
| Aaron I. Davis13D, may seek influence with 4 related filers | 7.8% | October 15, 2024 |
| Dapice Joshua J.13G, passive with 27 related filers | 7.8% | May 11, 2026 |
| TCG Crossover GP II, LLC13G, passive with 2 related filers | 7% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 6.9% | May 6, 2026 |
| BCTG Holdings, LLC13D, may seek influence with 3 related filers | 6.5% | November 7, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 247 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 13,900,620 | +600,000 |
| BlackRock, Inc. | 12,438,444 | +3,690,399 |
| Fmr LLC | 12,333,339 | +2,427,420 |
| Farallon Capital Management, L.L.C. | 12,277,000 | +3,179,589 |
| Boxer Capital Management, LLC | 10,876,219 | 0 |
| Goldman Sachs Group Inc | 9,980,620 | +4,904,228 |
| TCG Crossover Management, LLC | 9,081,201 | -1,449,870 |
| Paradigm Biocapital Advisors LP | 6,357,523 | +2,347,844 |
| Siren, L.L.C. | 6,179,364 | +522,259 |
| State Street Corp | 5,979,806 | +1,327,912 |
| Vanguard Capital Management LLC | 5,957,348 | +795,917 |
| Adage Capital Partners GP, L.L.C. | 5,600,000 | -7,209,485 |
| Jupiter Topco LLC | 5,056,352 | new |
| Deep Track Capital, LP | 4,200,000 | +1,450,000 |
| Deerfield Management Company, L.P. | 4,190,611 | +43,798 |
| Woodline Partners LP | 4,000,567 | -3,999,446 |
| Trv GP IV, LLC | 6,374,574 | 0 |
| Geode Capital Management, LLC | 3,742,791 | +1,067,014 |
| Perceptive Advisors LLC | 3,377,000 | +2,568,847 |
| Seven Fleet Capital Management LP | 3,228,144 | +2,726,132 |
Insiders
11 insiders reported holding 2,500,431 shares in total, about $60.8M at the last price.
| Holder | Shares |
|---|---|
| Weber BarbaraDirector, Executive Chair, Director | 1,629,254 |
| Peters MaltePresident & CEO, Director | 367,500 |
| Beckman DaniellaChief Financial Officer | 184,297 |
| Crystal AdamPresident, R&D | 115,743 |
| Newcomb JessicaPrincipal Accounting Officer | 52,090 |
| Rothenberg MaceDirector | 41,500 |
| Gall MatthewChief Financial Officer | 40,000 |
| Ketchum John BDirector | 24,937 |
| Lee SungDirector | 22,870 |
| Calhoun Lesley AnnDirector | 16,500 |
Questions about TNGX
What does Tango Therapeutics, Inc. do?
Tango Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TNGX. Its shares trade on NASDAQ under the ticker TNGX.
What is Tango Therapeutics, Inc.'s net worth?
Tango Therapeutics, Inc. has a market value (market cap) of $3.6B at the latest share price, and shareholders' equity of $980.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tango Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $208M.
How much revenue does Tango Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Tango Therapeutics, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Tango Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Tango Therapeutics, Inc.'s next earnings report?
Tango Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TNGX with
Follow TNGX
Get an email when Tango Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tango Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.